Core Viewpoint - New Element Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] Group 1: Company Overview - New Element Pharmaceuticals is a biotechnology company focused on developing therapies for metabolic, inflammatory, and cardiovascular diseases [1] - The company's core product, ABP-671, is a URAT1 inhibitor currently undergoing Phase 2b/3 clinical trials in China and the United States, with the potential to become a first-line treatment for gout and hyperuricemia [1] - ABP-671 has also shown preclinical potential in treating chronic kidney disease (CKD) with hyperuricemia and refractory gout [1] Group 2: Product Pipeline - The company has a drug discovery platform based on structural metabolic analysis, which has led to the development of clinical-stage candidates ABP-671 and ABP-745 [1] - In addition to its clinical candidates, the company has a series of preclinical pipelines, including AT6616, ABP-6016, and ABP-6118 [1]